Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX103 in treatment-refractory Crohn's disease
NCT06721962Phase 2Recruiting
- Sponsor
- Tr1X
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Regulatory T Cells (Tregs), Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of TRX103 in Crohn's disease (5 cohorts), sponsored by Tr1X. Primary endpoint: Safety and Tolerability of TRX103 Infusion at 12 months. Started May 2025; status: recruiting.
02
Drugs
TRX103
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06721962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721962.